Evidence Over Determinism: The Bar for AI in Clinical Trials

TL;DR: Regulated clinical environments do not require perfection from every process or system. They require control, evidence, traceability, accountability, and fitness for intended use. The clinical teams seeing the most success with AI are the ones evaluating it through that lens, and moving forward with confidence.

‍

Why This Matters

AI has tremendous potential to transform clinical trials because today's operating model is increasingly burdened by fragmented systems, delayed data, complex protocols, and manual workflows. Realizing that potential requires moving beyond a narrow debate about determinism and instead focusing on what matters in regulated clinical environments: systems that are accurate, traceable, governed, and fit for purpose. The future of clinical AI will be defined not by perfect consistency in every response, but by robust quality controls, transparent governance, accountable human oversight, and the ability to deliver trustworthy insights that help teams make better decisions and bring therapies to patients faster.

‍

The Right Question: Not Whether, But How

The FDA was the first government agency to adopt AI department-wide. That is not a minor footnote. It is a signal from the world's most influential drug regulator about where the industry is headed and how AI should be evaluated within it.

‍
The FDA's January 2025 draft guidance on AI for drug and biological products describes a risk-based credibility assessment tied to the model's specific context of use. The emphasis is on how AI is being used, what question it is intended to address, what decisions it may influence, and what evidence supports its credibility in that context. That is the frame the best thinkers in clinical development are already applying.

‍
The most effective clinical AI programs are not asking whether AI can be trusted. They are asking the right operational questions: What is the system being asked to do? What data does it rely on? What controls are in place? Where does human review remain required? That precise evaluation is what separates teams moving forward with confidence from those stuck in broad, undifferentiated caution that slows innovation without improving quality.

‍

Clinical Trials Have Always Managed Risk Through Controls

This is not new territory. Clinical trials have never been fully deterministic environments. They are deeply human processes. Protocols are interpreted by investigators and site teams. Data are entered, reviewed, cleaned, queried, reconciled, and interpreted by people. Regulated environments have always depended on quality systems to manage risk in inherently variable processes.

The same quality mindset applies to AI. The organizations leading in this space are evaluating AI the same way they evaluate any regulated technology: Does the system retrieve the right data? Does it respect permissions? Are outputs traceable and validated against intended use? Is it monitored over time and supported by appropriate governance? Higher-risk applications receive proportionately stronger controls. Lower-risk operational support moves forward with appropriate but lighter oversight. That is not a lower standard. It is the right standard, applied with precision.

‍

Not Every AI Use Case Carries the Same Risk

Industry leaders understand that a dashboard summarizing enrollment performance carries a different level of risk than a system supporting a dosing decision. An AI assistant helping a clinical operations leader understand query aging is not the same as an AI-generated output used directly in a regulatory submission.

Strong governance gives teams a reliable way to distinguish between low-risk operational support, medium-risk decision support, and higher-risk workflows that require more formal validation. When governance is designed well, it enables appropriate use rather than preventing all use. The teams that have built this framework are the ones accelerating, while others wait.

‍

Building Trustworthy AI for Regulated Clinical Operations

Trust in clinical AI is not built on whether every response is word-for-word identical. It is built on evidence that systems are accurate, traceable, governed, and reliable enough for their intended use. Trustworthy AI begins with disciplined engineering and quality practices: validated data pipelines, source-to-target mapping verification, automated regression testing, benchmark question sets, role-based access controls, audit logs, and post-release monitoring.

These are not aspirational practices. They serve as the foundation Vivo was built on. As an AI-native platform purpose-built for clinical trial operations, we work alongside clinical development teams every day, in live trials, across oncology, immunology, rare disease, and neuroscience. We have navigated these questions in production, not in theory.

‍

The Path Forward

The future of clinical AI will be defined by robust quality controls, transparent governance, accountable human oversight, and the ability to deliver trustworthy insights that help teams make better decisions and bring therapies to patients faster.

The regulators have spoken. The most forward-thinking sponsors, CROs, and clinical development teams are moving. This is the intersection where OmniScience lives: clinical data science, AI engineering, and the operational realities of running trials in regulated environments. We have built the infrastructure, earned the trust of clinical teams running live trials, and developed the frameworks that make responsible adoption practical.

What we have seen working alongside these teams is that when the right foundation is in place, the possibilities shift entirely. Questions get answered in seconds instead of days. Risks surface before they escalate. Teams stop managing data and start leading their trials. That transformation is what drives us, and ultimately, it is what gets life-changing treatments to the patients who have been waiting for them.

If your organization is navigating how to evaluate, adopt, and govern AI in clinical operations, we would love to be part of that conversation.